We’re excited to share that The Alliance for Artificial Intelligence in Healthcare (AAIH) highlighted our recent publication in the Journal of Chemical Information and Modeling (JCIM).
The feature recognizes our discovery of a novel LRRK2 inhibitor—a promising lead for Parkinson’s disease—and marks the first peer-reviewed paper from the BIOPTIC B1 team.
Using BIOPTIC B1, our AI-powered platform, we screened billions of compounds and surfaced strong candidates against LRRK2, a key driver of Parkinson’s progression—in weeks, not years.
This acknowledgment from AAIH underscores how rigorous, transparent AI can accelerate therapeutic discovery and bring impactful medicines to patients faster.
—
Excerpted highlights from AAIH:
• “Optic has published a groundbreaking study… detailing the discovery of a novel LRRK2 inhibitor… first peer-reviewed publication from the team behind BIOPTIC B1.”
• “Using BIOPTIC B1, the team screened billions of compounds… completed in weeks rather than years.”
